Skip Navigation

Skip Navigation

Issue No. 1  | January 06, 2012
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Announces New Members

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (a working group of the Office of AIDS Research Council) is pleased to welcome four new members to the Panel. The new members will begin a 4-year term starting in March 2012.

  • Judith Aberg, M.D. (New York University)
  • Adaora Adimora, M.D., M.P.H. (University of North Carolina)
  • Phyllis Tien, M.D., M.S. (University of California, San Francisco)
  • Rochelle Walensky, M.D., M.P.H. (Massachusetts General Hospital/Harvard Medical School)


FDA Expands Use of Raltegravir (Isentress) to Treat HIV Infection in Children and Adolescents

“Isentress (raltegravir) was approved [on December 21, 2011] by the U.S. Food and Drug Administration for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2-18. ...

“Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. Because the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.

“A single, multi-center clinical trial of 96 children and adolescents ages 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.”

The updated label will be available at the FDA Web site.

More information is available:


Recent News About NIAID-Sponsored Studies

The NIH recently announced news about the following two NIAID-sponsored research studies:

  • January 4, 2012: Experimental Vaccine Partially Protects Monkeys from HIV-Like Infection

    “New vaccine research in monkeys suggests that scientists are homing in on the critical ingredients of a protective HIV vaccine and identifies new HIV vaccine candidates to test in human clinical trials. The research, which appears online in Nature on Jan. 4, was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.”

    For more information, read the NIAID press release.
     
  • December 22, 2011: HIV Study Named 2011 Breakthrough of the Year by Science

    “The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year. The study found that if HIV-infected heterosexual individuals begin taking antiretroviral medicines when their immune systems are relatively healthy as opposed to delaying therapy until the disease has advanced, they are 96 percent less likely to transmit the virus to their uninfected partners.”

    For more information, read the NIH press release.


Twitter - Stay connected FaceBook - Stay connected
ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228